Non-communicable diseases: The prickly problem of access to insulin

BMJ (Online)

Volumn 343, Issue 7823, 2011, Pages

  Cohen, Deborah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG USE; FEMALE; FUNDING; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HOUSEHOLD; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LAW; LIFE EXPECTANCY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHOOL CHILD; SEX DIFFERENCE; ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; LEGAL ASPECT;

DEVELOPING COUNTRIES; DIABETES MELLITUS; DRUG COSTS; DRUG INDUSTRY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84859000593     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5782     Document Type: Review

References (30)

1. Bliss M. Discovery of insulin. University of Chicago Press, 1984.
2. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low-income countries. Bull World Health Organ 2007;85:279-88. (Pubitemid 46556727)
3. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. Lancet 2006;368:1689-95. (Pubitemid 46070151)
4. International Diabetes Federation. Diabetes atlas. http://archive. diabetesatlas.org/map.
5. Cohen D. The final declaration for the UN summit on NCDs. 9 Sep 2011. http://blogs.bmj.com/bmj/2011/09/09/deborah-cohen-the-final-declaration-for-the- un-summit-on-ncds-2/?utm-source=feedburner&utm-medium=feed&utm-campaign.
6. WHO. Expert committee on the selection and use of essential medicines. 2011. www.who.int/selection-medicines/committees/expert/18/en/index.html.
7. Holden SE, Poole CD, Morgan CLI, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011;1:e000258 [forthcoming].
8. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. Clinical guideline 66. 2008. www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf.
9. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2008;373:240-9.
10. Bennett S. WHO should buy their drugs in bulk for poor, Novo CEO says. Bloomberg Businessweek 2011 Sep 6. www.businessweek.com/news/2011-09-06/who- should-buydiabetes-drugs-in-bulk-for-poor-novo-ceo-says.html
11. Ghangurde A.Pfizer in investment phase in India as it moves into diabetes and branded generics. SCRIP 2011 Aug 16. www.scripintelligence.com/business/ Pfizer-in-investmentphase-in-India-as-it-moves-into-diabetes-and-branded- generics-319980.
12. Senate joint resolution No 397. 2007. http://leg1.state.va.us/cgi-bin/ legp504.exe?071+ful+SJ397.
13. European Medicines Agency. Withdrawal assessment report for insulin human rapid Marvel. www.ema.europa.eu/docs/en-GB/document-library/Application- withdrawal-assessment-report/2010/01/WC500067086.pdf.
14. NCD Alliance. Access to essential medicines and technologies for NCDS. http://ncdalliance.org/sites/default/files/resource-files/ NCD%20Alliance%20briefing%20paper%20- %20Access%20to%20Essential%20Medicines%20and%20Technologies%20for%20NCDs% 20%28full%20references%29.pdf.
15. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource-poor settings. Diabetes Res Clin Pract 2010;88:217-21.
16. Diabetes Leadership Forum Africa. Diabetes: the hidden pandemic and its impact on sub-Saharan Africa. 2010. www.changingdiabetesbarometer.com/docs/ Diabetes%20in%20sub-saharan%20Africa.pdf.
17. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.
18. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6:CD008143.
19. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-85.
20. Institute for Quality and Efficiency in Health Care. Benefit assessment of long-term blood glucose lowering to near normal levels in patients with type 2 diabetes mellitus. IQWIG, 2011.
21. Ghangurde A. Sanofi-Aventis expanding diabetes range in India. SCRIP 2010; Dec 1.
22. International Diabetes Federation. Annual report 2010. www.idf.org/sites/default/files/Annual-Report-2010-FINAL-EN-0.pdf.
23. International Diabetes Federation. Life for a child. http://www.idf.org/ lifeforachild/theprogramme.
24. Pagoda PR. Who we are. www.pagodapr.com/whoweare/1,Sir-Michael-Hirst.html
25. Pagoda PR. Our clients. www.pagodapr.com/ourclients/www.access2insulin. org.
26. Sawacki PT. Does additional benefit justify additional costs of insulin analogues? BMJ 2011;343:d5858.
27. International Diabetes Federation Global Guideline on pregnancy and diabetes. www.idf.org/guidelines/pregnancy-and-diabetes.
28. Abdraimova A, Beran D. Report on the rapid assessment protocol for insulin access in Kyrgyzstan. International Insulin Foundation, 2009.
29. NovoNordisk. Large study to investigate diabetes in emerging markets. Share 2009 Nov:12. www.novonordisk.com/images/investors/share-magazine/2009/ Share-Nov2009-UK.pdf.
30. Strumello S. Could generic insulin soon hit the market. 2007. www.slideshare.net/sstrumello/could-generic-insulin-soon-hit-the-us-market.